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Social deﬁcits are a hallmark feature of autism spectrum disorder (ASD) and related developmental
syndromes. Although there is no standard treatment for social dysfunction, clinical studies have iden-
tiﬁed oxytocin as a potential therapeutic with prosocial efﬁcacy. We have previously reported that pe-
ripheral oxytocin treatment can increase sociability and ameliorate repetitive stereotypy in adolescent
mice from the C58/J model of ASD-like behavior. In the present study, we determined that prosocial
oxytocin effects were not limited to the adolescent period, since C58/J mice, tested in adulthood,
demonstrated signiﬁcant social preference up to 2 weeks following subchronic oxytocin treatment.
Oxytocin was also evaluated in adult mice with underexpression of the N-methyl-D-aspartate receptor
NR1 subunit (encoded by Grin1), a genetic model of autism- and schizophrenia-like behavior. Subchronic
oxytocin had striking prosocial efﬁcacy in male Grin1 knockdown mice; in contrast, chronic regimens
with clozapine (66 mg/kg/day) or risperidone (2 mg/kg/day) failed to reverse deﬁcits in sociability.
Neither the subchronic oxytocin regimen, nor chronic treatment with clozapine or risperidone, reversed
impaired prepulse inhibition in the Grin1 knockdown mice. Overall, these studies demonstrate oxytocin
can enhance sociability in mouse models with divergent genotypes and behavioral proﬁles, adding to the
evidence that this neurohormone could have therapeutic prosocial efﬁcacy across a spectrum of
developmental disorders.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Oxytocin is a neuropeptide hormone with a long-recognized
role in maternal responses and mother-infant bonding. Clinical
studies in subjects with autism spectrum disorder (ASD) have
found that acute oxytocin can improve social function and decrease
motor stereotypy and other forms of repetitive behavior (AndariDevelopmental Disabilities,
icine, Chapel Hill, NC 27599,
, Corporate Strategy Division,
partment of Psychology and
09-0345, USA.
Ltd. This is an open access article uet al., 2010; Guastella et al., 2010; Hollander et al., 2003, 2007).
Further, Hall et al. (2012) observed that acute oxytocin could
ameliorate indicators of social anxiety in male adolescents and
adults with fragile X syndrome. One recent study using a 5-week
regimen with intranasal oxytocin in young children (3e8 years in
age) with ASD found improved social responsivity, although no
concomitant reduction in abnormal repetitive behavior (Yatawara
et al., 2015). These initial reports also suggest that oxytocin might
not have the same potential for adverse events as found with more
powerful psychoactive agents, such as risperidone or ﬂuoxetine,
used to treat co-morbid symptoms in ASD (Mahajan et al., 2012;
West et al., 2009; Yatawara et al., 2015). However, not all clinical
trials using intranasal application of oxytocin to ameliorate social
deﬁcits or other symptoms have proven successful (Anagnostou
et al., 2012; Cacciotti-Saija et al., 2015; Dadds et al., 2014),nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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apeutic agent.
Our research group has reported that peripheral administration
of oxytocin can alleviate sociability deﬁcits in twomouse models of
autism-like behavior, the BALB/cByJ and C58/J inbred strains (Teng
et al., 2013). Previous work has shown that BALB/cByJ and the
related substrain, BALB/cJ, are characterized by a lack of social
preference in a three-chambered choice task and by anxiety-like
behavior in an elevated plus maze (Brodkin et al., 2004; Moy
et al., 2007; Sankoorikal et al., 2006). Our previous study showed
that, while acute oxytocin treatment did not reverse social deﬁcits,
a subchronic regimen of four injections, given across 8e9 days, led
to signiﬁcant sociability in adolescent BALB/cByJ mice, tested 24 h
following the ﬁnal dose (Teng et al., 2013).
Our group has also investigated oxytocin effects in the C58/J
inbred strain, which has low sociability in a three-chambered task,
deﬁcits in social transmission of food preference, and overt repet-
itive behavior (Moy et al., 2008b, 2014; Muehlmann et al., 2012;
Ryan et al., 2010; Silverman et al., 2012). We found that a sub-
chronic oxytocin regimen had prosocial effects in adolescent male
and female C58/J mice, with increases in social preference
emerging one or two weeks following treatment (Teng et al., 2013).
Acute, but not subchronic, administration of oxytocin led to sig-
niﬁcant decreases in abnormal repetitive behavior.
In the present studies, we investigated whether oxytocin would
exert prosocial effects in adult C58/J mice, similar to our ﬁndings in
adolescents. Motivation for social afﬁliation and regulation of social
interactions can differ between adolescents and adults (Spear,
2011; see also Ernst et al., 2006). For example, Morales and Spear
(2014) reported that, in a two-chamber test box, adolescent rats
had higher levels of social interaction and a higher frequency of
crossovers toward an unfamiliar social partner than adult rats.
These data support a greater sensitivity to the rewarding aspects of
novel social stimuli during adolescence, and raise the possibility
that oxytocin might be most effective at this stage of development,
while long-term social deﬁcits in adults could be more recalcitrant
to reversal.
The present studies also extended the evaluation of oxytocin to
a thirdmodel of ASD-like behavior and synaptopathology, the Grin1
knockdown mouse. Although the mechanistic basis for ASD is not
known, genetic analyses in human populations have implicated
several genes important for synaptic function, including GRIN1,
which encodes the obligatory NMDAR1 subunit of the N-methyl-D-
aspartate (NMDA) receptor (Abrahams and Geschwind, 2008;
Voineagu et al., 2011; Zeidan-Chulia et al., 2014); however, not all
studies have found an positive association between ASD and GRIN1
(e.g. Sanders et al., 2015; Tarabeux et al., 2011). There is growing
evidence that alterations in NMDA receptor signaling play a role in
ASD and other neurodevelopmental disorders (for recent reviews,
see Burnashev and Szepetowski, 2015; Lee et al., 2015), including
reports that autism candidate genes, such as NEUROLIGIN-1 and
SHANK3, serve as regulators of NMDA receptor function (Budreck
et al., 2013; Duffney et al., 2013). Mice with reduced Grin1
expression recapitulate many ASD features, including overt social
deﬁcits, inappropriate social interaction, abnormal repetitive
behavior, self-injurious responses, and impaired sensorimotor
gating (Billingslea et al., 2014; Duncan et al., 2004; Finlay et al.,
2015; Gandal et al., 2012; Milenkovic et al., 2014; Mohn et al.,
1999; Moy et al., 2008a, 2012, 2014; Saunders et al., 2013). We
determined the effects of oxytocin on social deﬁcits, reduced pre-
pulse inhibition, and hyperactivity in Grin1 knockdown mice. We
also examined whether chronic regimens with atypical antipsy-
chotics, initiated in early adolescence or young adulthood, have
prosocial efﬁcacy in the Grin1 knockdown model.2. Methods and materials
2.1. Animals
C58/J mice were offspring of breeding pairs obtained from
Jackson Laboratories (Bar Harbor, ME). Grin1neo/neomice engineered
with a neomycin resistance gene (neo) in intron 20 of the Grin1
locus and Grin1þ/þ littermate controls were generated from het-
erozygous breeder pairs, as previously described (Mohn et al., 1999;
Moy et al., 2012). Experimenters conducting the behavioral tests
were blind to genotype.
Mice were maintained in groups of 2e4 animals per poly-
carbonate mouse cage, in a room under a 12-h light/dark cycle
(lights off at 7pm). ProLab RMH 3000 chow and water were pro-
vided ad libitum. All animal procedures were conducted in strict
compliance with the animal welfare policies set by the National
Institutes of Health and the University of North Carolina (UNC), and
were approved by the UNC Institutional Animal Care and Use
Committee.
2.2. Drug treatment regimens
2.2.1. Oxytocin
Oxytocin (Bachem, Torrance, CA) was dissolved in saline con-
taining 0.002% glacial acetic acid. All injections were administered
IP (intraperitoneal) in a volume of 10.0 ml/kg. For the subchronic
regimen, mice were given four injections of vehicle or oxytocin (1.0
or 2.0 mg/kg) across 8e9 days, with at least 48 h between each
injection (i.e. mice were injected on sequential weekdays WFMW
or WFTTh). Experimenters conducting the behavioral tests were
blind to drug treatments.
2.2.2. Chronic clozapine and risperidone regimens in Grin1 mice
Chronic regimens with clozapine (30 days; 66 mg/kg/day) or
risperidone (21 days; 2.0 mg/kg/day) were initiated with a pre-
liminary ramping up of drug dose to minimize sedative or other
side effects at the beginning of treatment. Doses were selected to
reﬂect therapeutic dosage in humans, determined by clinical levels
of dopamine D2 receptor occupancy (Kapur et al., 2003;Wadenberg
et al., 2001).
Slow-release pellets were utilized for chronic clozapine
administration because of difﬁculties in higher-dose drug solubility
for osmotic minipumps (Kapur et al., 2003) and issues with variable
plasma levels during administration in drinking water (Perez-
Costas et al., 2008). At 11e14 weeks of age, mice were brieﬂy
anesthetized by isoﬂurane and implanted, using a trocar injector,
with subcutaneous 30-day slow-release clozapine or sham tablets
(Innovative Research of America, Sarasota, FL). The target dosage of
66 mg/kg/day was reached by incremental stages across 8 days,
with 2e3 total pellet implants per subject. Following each implant,
the trocar injection site was sealed using Tissuemend (Jeffers Inc.,
Dothan, AL).
For the initial acclimation to risperidone (SigmaeAldrich, St.
Louis, MO), adolescent mice (starting at age 33e38 days) received 3
IP injections of either saline vehicle containing 1% glacial acetic acid
(adjusted to pH 5.5) or risperidone (0.3 mg/kg), with 2e3 days
between each injection. One day following the third injection, mice
were brieﬂy anesthetized by isoﬂurane and implanted with a
subcutaneous osmotic minipump (Model 1002; Alzet; Braintree Sci.
Inc., Braintree, MA) containing either risperidone (2.0 mg/kg/day)
or vehicle, for a 14-day delivery. At the end of the 14-day period,
mice were again anesthetized, and the depleted 14-day pump was
replaced by a new 7-day pump (Model 1007D) for the ﬁnal phase of
the 21-day regimen. This pump replacement allowed dosage to be
adjusted for increased body weight during the chronic risperidone
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2.3. C58/J inbred strain model
Oxytocin has persistent effects on social behavior in adolescent
C58/J mice (Teng et al., 2013). In this study, we investigated
whether social deﬁcits in adult C58/J mice could also be reversed by
oxytocin treatment. Subjects were male and female mice (7e8 of
each sex per treatment group; 5e6 months of age at time of
testing), treated using a subchronic regimen of vehicle or 1.0 mg/kg
oxytocin. Mice were tested in the 3-chamber choice task at two
time points, 24 h and 2 wk post-treatment.
2.4. Grin1 knockdown model
2.4.1. Acute oxytocin effects on open ﬁeld activity
Subjects were 7e9 male mice and 6e9 female mice of each
genotype (Grin1þ/þ and Grin1neo/neo) per treatment group, 8e11
months in age, taken from 12 litters. Each mouse was given 3 1-hr
tests, one with vehicle pretreatment and one with each dose of
oxytocin (0.5 and 1.0 mg/kg), with 1 week between each test. A
balanced treatment design was used, so that order of treatments
was balanced for genotype and sex across the 3 tests. Mice were
placed into the activity chambers immediately after each
treatment.
2.4.2. Acute oxytocin effects on sensorimotor gating
Subjects were 12e13 male mice and 10e13 female mice of each
genotype (Grin1þ/þ and Grin1neo/neo), 5e7 months of age, taken
from 23 litters. The acoustic startle test was conducted 50 min
following treatment with vehicle or oxytocin (1.0 mg/kg). Each
mousewas given 2 sessions, onewith vehicle pretreatment and one
with oxytocin pretreatment, with 1 week between each session. A
balanced treatment designwas used, so that order of treatment was
balanced by genotype and sex across the 2 tests.
2.4.3. Subchronic oxytocin regimen
Subjects were 8e9 male mice and 8e10 female mice of each
genotype (Grin1þ/þ and Grin1neo/neo) per treatment group (vehicle
or 1.0 mg/kg oxytocin), tested at 3e5 months of age, taken from 29
litters. Each subject was tested in the 3-chamber choice task
approximately 24 h following the ﬁnal treatment. Mice were
further tested in an acoustic startle assay 48 h post-treatment, and
the marble-burying assay 4e5 days post-treatment. Because no
genotype or treatment effects were observed in the female groups,
an additional set of female Grin1 mice (6e8 of each genotype, 7
months in age, taken from 5 litters) were given subchronic treat-
ment with a higher dose of oxytocin (2.0 mg/kg) and tested in the
3-chamber choice task.
2.4.4. Chronic clozapine
Subjects were 4e8 male mice and 4e6 female mice of each
genotype per treatment group, 3e4 months of age at time of
behavioral testing, taken from 23 litters. Mice were tested in the 3-
chamber choice task 32e35 days following the ﬁnal subcutaneous
implant of a 30-day slow-release pellet. Mice were also tested in an
acoustic startle assay at two time points, 15e16 days and 35e38
days following the ﬁnal pellet implantation.
2.4.5. Chronic risperidone
Subjects were 6e9 male mice and 5e8 female mice of each
genotype per treatment group, 60e70 days of age at time of
behavioral testing, taken from 23 litters. Mice were tested in the 3-
chamber choice task 23e26 days following the start of a 21-day
chronic regimen (administered by osmotic minipump). Mice werealso tested in an acoustic startle assay 24e27 days and a marble-
burying task 28e29 days after initiation of the chronic regimen.
2.5. Behavioral testing procedures
2.5.1. Three-chamber social choice test
Social approach was assessed in a 3-chamber Plexiglas box
(procedure modiﬁed from Moy et al., 2007). The test started with a
10-min habituation phase, with free exploration of the empty test
box, followed by a 10-min test for sociability. During the sociability
phase, the test mouse was given a choice between an unfamiliar
stranger mouse (a sex-matched C57BL/6J adult), contained in a
Plexiglas cage placed in one side chamber, or an empty Plexiglas
cage in the opposite side chamber. Cages were drilled with holes to
allow investigation of the stranger. Measures were taken of the
time spent in each chamber, time spent in 5 cm proximity to each
cage, and number of entries into each chamber, by an automated
image tracking system (Ethovision, Noldus Information Technology,
Wageningen, the Netherlands).
2.5.2. Open ﬁeld test
Activity was assessed in a photocell-equipped automated open
ﬁeld (41 cm  41 cm  30 cm; Versamax System, AccuScan In-
struments, Columbus, OH). Measures were taken of total distance
traveled, rearing movements, and time spent in the center region of
the chamber, for each 1-hr test.
2.5.3. Acoustic startle test
Mice were evaluated for acoustic startle responses with an SR-
Lab system (San Diego Instruments). Each test session consisted
of a 5-min habituation period, followed by 42 trials: no-stimulus
trials, trials with the acoustic startle stimulus (40 ms; 120 dB)
alone, and trials in which a prepulse stimulus (20 ms; either 74, 78,
82, 86, or 90 dB) had onset 100 ms before the onset of the startle
stimulus. The different trial types were presented in blocks of 7, in
randomized order within each block, with an average intertrial
interval of 15 s. Measures were taken of startle amplitude, deﬁned
as the peak response during a 65-msec sampling window following
onset of the startle stimulus. PPI was calculated as 100 - [(response
amplitude for prepulse stimulus and startle stimulus together/
response amplitude for startle stimulus alone) x 100].
2.5.4. Marble-burying assay
Each subject was tested in a polycarbonate mouse cage located
in a sound-attenuating chamber with ceiling light and fan. The cage
contained 5 cm deep clean corncob bedding, with 20 black glass
marbles (14 mm diameter) arranged in an equidistant 5  4 array
on top of the bedding. Measures were taken of the number of
marbles covered 2/3 or more by the bedding after a 30 min test.
2.6. Statistical analysis
Data were analyzed with one-way, two-way, or repeated mea-
sures analysis of variance (ANOVA), with factors treatment, sex, and
genotype (dependent on experiment), using Statview software
(SAS, Cary, NC). Repeated measures included side of social test box,
test session, or prepulse sound level. Separate repeated measures
ANOVAs were conducted for each sex to determine oxytocin effects
on sociability in male and female mice. Within-treatment repeated
measures ANOVAs were used to determine side preference in the
social choice test. Fisher's protected least-signiﬁcant difference
(PLSD) tests were used for comparing group means only when a
signiﬁcant F value was determined by ANOVA. Signiﬁcance was set
at p < 0.05.
Fig. 2. Effects of subchronic oxytocin on time spent in proximity to a stranger mouse.
Testing occurred at 24 h, and again at 2 wk, following the ﬁnal treatment. During the
second test, only the oxytocin treatment groups had signiﬁcant social preference.
*p < 0.05, within-group comparison to empty cage side.
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3.1. Prosocial oxytocin effects in adult C58/J mice
3.1.1. Sociability in male and female C58/J mice
Previous work in our laboratory has shown that subchronic
oxytocin has persistent prosocial effects in adolescent C58/J mice
(Teng et al., 2013). In the present study, both male and female adult
C58/J mice (ages 5e6 months) treated with oxytocin, but not
vehicle, had signiﬁcant preference for spending time in the stranger
side of a 3-chamber box (Fig. 1). In the male mice, the prosocial
oxytocin effects were evident at 24 h and 2 wk post-treatment
[within-treatment group post-hoc analyses following signiﬁcant
effect of side, F(1,14) ¼ 9.38, p ¼ 0.0084; determined by a 3-way
repeated measures ANOVA, with factors treatment, side, and time
point for testing] (Fig. 1A, B). In the male groups, there was a non-
signiﬁcant trend for a treatment  side interaction [F(1,14) ¼ 3.8,
p ¼ 0.0717]. Female mice treated with oxytocin demonstrated
signiﬁcant preference for the stranger side only at the 24-h time
point [within-treatment group post-hoc analyses following signif-
icant effect of side, F(1,13) ¼ 11.40, p ¼ 0.005] (Fig. 1C).
3.1.2. Preference for social proximity in male and female C58/J mice
We have previously reported that adolescent C58/J male mice
have positive sociability with the measure of snifﬁng directed to-
wards a stranger mouse (Moy et al., 2008b). The present study used
a similar measure, proximity to each cage. In the ﬁrst test, given
24 h following the subchronic regimen, the C58/J male mice treated
with vehicle, but not oxytocin, spent signiﬁcantly more time in
proximity to the stranger mouse than the empty cage (Fig. 2A).
However, during second test, only the oxytocin-treated groupFig. 1. Persistent prosocial effects of subchronic oxytocin in adult C58/J mice. Subjects
were tested for sociability in a 3-chamber choice task. The subchronic regimen con-
sisted of 4 treatments with either vehicle or oxytocin (1.0 mg/kg, IP) across an 8e9 day
period. Mice were tested at 24 h, and again at 2 wk, following the ﬁnal treatment.
*p < 0.05, within-group comparison to empty cage side.demonstrated signiﬁcant social preference [within-treatment
group post-hoc analyses following signiﬁcant effect of side,
F(1,14) ¼ 6.66, p ¼ 0.0218] (Fig. 2B). In the female groups, mice
treated with oxytocin demonstrated signiﬁcant preference for the
stranger side at both the 24-hr and 2-wk time points [within-
treatment group post-hoc analyses following signiﬁcant effect of
side, F(1,13) ¼ 34.29, p < 0.0001] (Fig. 2C, D). In contrast, vehicle-
treated female mice failed to demonstrate positive sociability
with the proximity measure in either test.
3.1.3. Oxytocin effects on entries in the 3-chamber test
Subchronic oxytocin did not alter number of entries during the
test in the C58/J groups, indicating prosocial effects were not due to
general changes in activity or exploration (Fig. 3). Number of entries
is not typically used as an index for social approach; however, it is
notable that the male C58/J mice treated with oxytocin, but not
vehicle, showed signiﬁcantly more entries into the side containing
the stranger mouse during the ﬁrst social test [effect of side,
F(1,14) ¼ 8.89, p ¼ 0.0099] (Fig. 3A).
3.2. Acute oxytocin effects in Grin1þ/þ and Grin1neo/neo mice
3.2.1. Acute oxytocin effects on hyperactivity in an open ﬁeld
This study determined whether acute oxytocin could reduce the
overt hyperactivity previously reported in Grin1 knockdown mice
(Duncan et al., 2004; Mohn et al., 1999; Moy et al., 2014). Three-way
repeated measures ANOVAs did not reveal signiﬁcant effects of sex
on performance in the open ﬁeld; therefore, data for males and
females were combined for analysis. In line with previous ﬁndings,
the Grin1neo/neo mice had higher levels of activity than wild-type
mice (Fig. 4A, B). Highly signiﬁcant main effects of genotype were
found for each measure [distance traveled, F(1,29) ¼ 14.04,
p ¼ 0.0008; rearing movements, F(1,29) ¼ 21.07, p < 0.0001; and
Fig. 3. Effects of subchronic oxytocin on side-chamber entries by C58/J mice. Overall
number of entries was not changed by oxytocin in either male or female mice. Testing
occurred at 24 h, and again at 2 wk, following the ﬁnal treatment. *p < 0.05, within-
group comparison to empty cage side.
Fig. 4. Effects of acute oxytocin on hyperactivity and sensorimotor gating deﬁcits in Grin1
immediately before a 1-hr open ﬁeld test. D, E) Vehicle or oxytocin (1.0 mg/kg, IP) was admi
#p < 0.05, within-genotype comparison to vehicle (Panel A).
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signiﬁcant effect of treatment was revealed for distance traveled
[F(2,58) ¼ 3.26, p ¼ 0.0456]. Post-hoc comparisons conﬁrmed that
the higher dose of oxytocin (1.0 mg/kg) led to a signiﬁcant decrease
in locomotor activity in the Grin1neo/neo mice. No effects of oxytocin
on activity were observed in the wild-type group.
3.2.2. Acute oxytocin effects on sensorimotor gating
Previous studies have shown that oxytocin and oxytocin re-
ceptor agonists can rescue sensorimotor gating deﬁcits in rodents
(Feifel et al., 2012; Ring et al., 2010). In this study, we determined if
acute administration of oxytocin could reverse impaired prepulse
inhibition in the Grin1neo/neo mice. A 3-way repeated measures
ANOVA did not indicate any signiﬁcant effects of sex; therefore,
data from males and females were combined. As shown in Fig. 4D
and E, the Grin1neo/neo mice demonstrated deﬁcits in prepulse in-
hibition at almost every decibel level, which were not reversed by
acute treatment with oxytocin [main effect of genotype,
F(1,46) ¼ 18.48, p < 0.0001; genotype  decibel interaction,
F(4,184) ¼ 7.59, p < 0.0001; no signiﬁcant effects of treatment].
3.3. Prosocial effects of subchronic oxytocin in Grin1neo/neo mice
3.3.1. Oxytocin effects on sociability in male Grin1 mice
Subchronic oxytocin (1.0 mg/kg) led to a striking increase in
sociability in male Grin1neo/neo mice, but not wild-type controls
(Fig. 5). As shown in Fig. 5A, only the Grin1 knockdownmice treated
with oxytocin had signiﬁcant social preference 24 h following the
ﬁnal injection. In contrast, male Grin1þ/þ mice had similar positive
sociability after either the vehicle or oxytocin regimen (Fig. 5B). A
repeated measures ANOVA on time spent in each chamber indi-
cated signiﬁcant 2-way interactions between genotype and side
[F(1,29) ¼ 5.92, p ¼ 0.0214], treatment and side [F(1,29) ¼ 10.04,
p¼ 0.0036], and a 3-way interaction between genotype, treatment,neo/neo mice. (A-C) Vehicle (Veh) or oxytocin (0.5 or 1.0 mg/kg, IP) was administered
nistered 50 min before an acoustic startle test. *p < 0.05, comparison to Grin1þ/þ mice.
Fig. 5. Prosocial effects of subchronic oxytocin in male Grin1neo/neo mice. Subjects were
tested for sociability in a 3-chamber choice task. The subchronic regimen consisted of 4
treatments with either vehicle or oxytocin (1.0 mg/kg, IP) across an 8e9 day period.
Grin1 mice were tested 24 h following the ﬁnal treatment. *p < 0.05, within-group
comparison to empty cage side. #p < 0.05, comparison to vehicle-treated group
(Panel A).
B.L. Teng et al. / Neuropharmacology 105 (2016) 61e7166and side [F(1,29)¼ 7.46, p¼ 0.0106]. A similar 3-way interaction for
genotype, treatment, and side emerged for the measure of prox-
imity to each cage (Fig. 5C and D) [F(1,24) ¼ 4.99, p ¼ 0.0351; data
missing for 5 mice tested before cage-zone tracking available].Fig. 6. Increased sociability in female Grin1neo/neo mice following subchronic treat-
ment with 2.0 mg/kg oxytocin. Subjects were tested for social preference in a 3-
chamber choice task. The subchronic regimen consisted of 4 treatments with either
vehicle, 1.0 mg/kg, or 2.0 mg/kg oxytocin (IP) across an 8e9 day period, with testing
24 h following the ﬁnal treatment. *p < 0.05, within-group comparison to empty cage
side. #p < 0.05, comparison to Grin1 wild-type (þ/þ).3.3.2. Lack of oxytocin effects on entries in male Grin1 mice
Subchronic oxytocin did not alter number of entries during the
test in the Grin1 groups, indicating prosocial effects were not due to
general changes in activity or exploration (Fig. 5). In the Grin1neo/neo
mice, oxytocin did not rescue deﬁcits in entry numbers (Fig. 5E)
[main effect of genotype, F(1,29) ¼ 97.02, p < 0.0001; and side,
F(1,29) ¼ 21.46, p < 0.0001]. In the Grin1þ/þ mice, only the
oxytocin-treated group showedmore entries into the stranger side,
versus the empty cage side (Fig. 5F) [within-treatment group post-
hoc analyses following signiﬁcant effect of side, F(1,14) ¼ 9.91,
p ¼ 0.0071].3.3.3. Oxytocin (1.0 and 2.0 mg/kg) effects on sociability in female
Grin1 mice
In contrast to the results from the male Grin1 mice, there were
no signiﬁcant effects of genotype or treatment (1.0 mg/kg oxytocin)
for measures of sociability in the female groups. Therefore, an
additional set of female mice was tested with a higher dose of
oxytocin, 2.0 mg/kg, using a subchronic regimen. Measures of
proximity are presented in Fig. 6A, since wild-type female mice
(from either treatment group) did not have signiﬁcant sociability by
the measure of time spent in each side of the test box. As shown in
Fig. 6A, the Grin1þ/þ and Grin1neo/neo mice treated with vehicle or
with 1.0 mg/kg oxytocin spent similar amounts of time in proximity
to the stranger mouse, although preference was only signiﬁcant in
the wild-type females [within-treatment group post-hoc analyses
following signiﬁcant effect of side, F(1,27) ¼ 23.11, p < 0.0001; no
effect of genotype or treatment; data missing for 4 mice tested
before cage-zone tracking available]. In contrast, following treat-
ment with the higher dose, the female Grin1neo/neo mice demon-
strated overt social preference and spent signiﬁcantly more time
than the wild-type mice in proximity to the stranger mouse [main
effect of genotype, F(1,12) ¼ 9.51, p ¼ 0.0095; effect of side,
F(1,12) ¼ 17.49, p ¼ 0.0013, and genotype  side interaction,
F(1,12) ¼ 6.42, p ¼ 0.0262].3.3.4. Lack of oxytocin effects on entries in female Grin1 mice
As observed in the male Grin1 groups, subchronic oxytocin did
not alter number of entries during the test in the female mice, or
reverse marked deﬁcits in the Grin1neo/neo groups (Fig. 6B). Highly
signiﬁcant main effects of genotype were observed in the mice
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2.0 mg/kg oxytocin [F(1,12) ¼ 25.7, p ¼ 0.0003].3.3.5. Lack of prosocial effects of chronic clozapine or risperidone in
Grin1neo/neo mice
In a search for therapeutic agents with prosocial efﬁcacy, our
research group evaluated chronic regimens with two atypical an-
tipsychotics, clozapine and risperidone. Overall, neither chronic
regimen reversed social deﬁcits in the Grin1neo/neo mice (Fig. 7).
Separate repeated measures ANOVAs for clozapine and risperidone
did not indicate any signiﬁcant effects of treatment or sex; there-
fore, data were combined for vehicle groups, and for males and
females. An overall repeated measures ANOVA for time spent in
each side revealed highly signiﬁcant effects of genotype
[F(1,93) ¼ 32.88, p < 0.0001] and side [F(1,93) ¼ 13.20, p ¼ 0.0005],
but not treatment. Interestingly, neither the wild-type nor Grin1neo/
neo groups demonstrated signiﬁcant social preference following the
chronic antipsychotic regimens (Fig. 7B and C). Further, the chronic
clozapine and risperidone treatments failed to alleviate the low
numbers of entries observed in the Grin1neo/neo groups [main effect
of genotype, F(1,93) ¼ 6.55, p ¼ 0.0121; and side, F(1,93) ¼ 6.42,
p ¼ 0.0129; but not treatment] (Fig. 7E and F).3.4. Failure to reverse sensorimotor gating deﬁcits in Grin1neo/neo
mice
On the day following the social approach test (48 h following the
ﬁnal injection with oxytocin or vehicle), the Grin1 mice were
further evaluated in an acoustic startle test. An overall repeated
measures ANOVA for prepulse inhibition did not indicate any sig-
niﬁcant effects for sex; therefore, data for male and female mice
were combined. As shown in Fig. 8A and B, the Grin1neo/neo mice
had overt deﬁcits in prepulse inhibition, which were not rescued by
the subchronic oxytocin regimen [main effect of genotype,
F(1,64) ¼ 31.64, p < 0.0001; genotype x sound level interaction,Fig. 7. Lack of signiﬁcant prosocial effects of chronic clozapine or chronic risperidone in G
(acclimated 30-day regimen; 66 mg/kg/day) or risperidone (acclimated 21-day regimen; 2
#p < 0.05, comparison to wild-type (þ/þ) group.F(4,246) ¼ 5.87, p ¼ 0.0002; no effects of treatment].
Similarly, chronic treatment with the antipsychotic drugs did
not reverse sensorimotor gating deﬁcits in the Grin1neo/neo mice.
Repeated measures ANOVAs did not indicate any signiﬁcant effects
for sex; therefore, data for male and female mice were combined.
As presented in Fig. 8C and D, the Grin1neo/neo mice in both the
vehicle and clozapine groups had reduced prepulse inhibition, in
comparison to wild-type [main effect of genotype, F(1,39) ¼ 14.56,
p ¼ 0.0005; genotype x sound level interaction, F(4,156) ¼ 3.06,
p ¼ 0.0184; no effects of treatment]. In the clozapine study, mice
were given a re-test on days 36e38 of the acclimated chronic
regimen; no signiﬁcant effects of clozapine were observed at this
additional time point (data not shown). A similar pattern was
observed following chronic risperidone, i.e. Grin1neo/neo mice in
both treatment groups had comparable deﬁcits in prepulse inhi-
bition (Fig. 8E, F) [main effect of genotype, F(1,52) ¼ 52.18,
p < 0.0001; genotype x sound level interaction, F(4,208) ¼ 5.63,
p ¼ 0.0003; no effects of treatment].3.5. Failure to reverse deﬁcits in marble-burying by Grin1neo/neo
mice
We have previously reported that Grin1 knockdown mice have
overt deﬁcits in a marble-burying task (Moy et al., 2014). In the
present study, Grin1mice were tested for marble-burying 4e5 days
after the ﬁnal treatment in a subchronic oxytocin regimen. As
shown in Fig. 9, oxytocin did not rescue deﬁcits in the Grin1neo/neo
mice. A 3-way ANOVA indicated a highly signiﬁcant effect of ge-
notype [F(1,50)¼ 1755.56, p < 0.0001], with no effects of treatment
or sex. Similarly, chronic risperidone did not have signiﬁcant effects
in a marble-burying test, conducted 28e29 days after the ﬁrst
pump implant. Both the vehicle- and risperidone-treated Grin1neo/
neo mice had profound deﬁcits in marble-burying, in comparison to
the wild-type mice [main effect of genotype, F(1,52) ¼ 1371.76,
p < 0.0001].rin1neo/neo mice. Testing occurred following chronic treatment with either clozapine
.0 mg/kg/day). *p < 0.05, within-genotype comparison to empty cage side (Panel A).
Fig. 8. No effects of subchronic oxytocin, or chronic clozapine or risperidone, on impaired sensorimotor gating in Grin1neo/neo mice. (A and B) Grin1wild-type (þ/þ) and knockdown
(neo/neo) mice were tested for prepulse inhibition of acoustic startle responses 48 h after the ﬁnal treatment in the subchronic regimen. C and D) Grin1 mice were tested on day
15e16 of the chronic clozapine regimen (66 mg/kg/day). Data were omitted from one male Grin1neo/neo mouse in the clozapine-treated group with extremely low startle amplitudes.
E and F) Grin1 mice were tested 3e6 days following the chronic risperidone (21 day; 2.0 mg/kg/day) regimen. *p < 0.05.
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The present studies demonstrated that oxytocin has prosocial
effects in C58/J and Grin1 knockdown mice, two genetically-
divergent mouse models of neurodevelopmental disorders. In
C58/J, signiﬁcant sociability was found up to 2 weeks following a
subchronic oxytocin regimen, supporting the premise that
repeated treatment with oxytocin can induce persistent alterations
in neural circuitry underlying aspects of social perception, moti-
vation, or reward. In the Grin1 knockdown model, subchronic
oxytocin led to a striking increase in sociability in the Grin1neo/neo
mice, without altering social approach in the wild-type group. In
both models, the enhanced social approach was observed in adult
mice, indicating that chronic social deﬁcits maintained beyond
adolescence are not recalcitrant to reversal. Together with our
previous ﬁndings in BALB/cByJ (Teng et al., 2013), these results
provide evidence that prosocial effects of oxytocin can be observedin genetically- and phenotypically-diverse mouse models of
autism-relevant behaviors, suggesting oxytocin could have gener-
alized efﬁcacy across subtypes of the autism spectrum disorders.
In mice, the IP route of injection has been shown to induce a
rapid increase in oxytocin levels of amygdala and hippocampus,
measured by sequential microdialysates across a 2 h period
(Neumann et al., 2013). Our studies used a subchronic regimenwith
four IP injections of oxytocin. Sobota et al. (2015) found that a
similar subchronic regimen with oxytocin increases social
approach, reduces anxiety-like behavior, and decreases amygdalar
activation in adolescent C57BL/6J mice. Other researchers have
reported that, in adolescent rats, more extended regimens (10 IP
injections of oxytocin) can lead to persistent increases in social
preference and decreases in anxiety-like behavior (Bowen et al.,
2011; Suraev et al., 2014). More recently, a study using mice with
targeted disruption of Cntnap2, an ASD candidate gene, found
increased sociability following a daily oxytocin regimen (from
Fig. 9. No effects of subchronic oxytocin or chronic risperidone treatment on marble-
burying deﬁcits in Grin1neo/neo mice. The marble-burying assay was conducted 4e5
days following the end of the subchronic regimen of oxytocin (OT) or vehicle (Veh), or
7e8 days following a chronic risperidone (RSP, 21 day; 2.0 mg/kg/day) regimen. Post-
hoc tests were not conducted, due to number of zero scores in the Grin1neo/neo groups.
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et al., 2015). The investigators also showed that acute treatment
with oxytocin had signiﬁcant effects on social approach, but not on
hyperactivity or perseverative responses, in the Cntnap2 model.
These results are in contrast to the present ﬁndings, in which acute
oxytocin signiﬁcantly attenuated overt hyperactivity in Grin1
knockdown mice. It is notable that, in the C58/J model, we have
previously reported that acute oxytocin signiﬁcantly decreases
abnormal repetitive behavior at a dose that does not reduce general
locomotion (Teng et al., 2013).
Not all studies have reported positive effects from chronic
oxytocin regimens in rodents. Bales et al. (2014) did not observe
enhanced sociability in BTBR TþItpr3tf/J mice following daily
treatment with oxytocin across 30 days. In monogamous prairie
voles, a 21-day regimen, from weaning age to puberty, led to
decreased time spent by male voles in side-to-side contact with a
familiar female partner (Bales et al., 2013). Huang et al. (2014)
found that 7-to-21 day regimens of intranasal oxytocin in C57BL/
6J led to decreased afﬁliative behavior, as well as decreased
oxytocin receptor binding in brain regions implicated in social
behavior and reward, including amygdala and nucleus accumbens.
A similar reduction in oxytocin receptor binding has been reported
following 15-day central infusion of oxytocin in C57BL/6 (Peters
et al., 2014). These latter studies suggest that hyperstimulation of
normal social circuitry with oxytocin might have detrimental
consequences in wild-type or control mice. Although Sobota et al.
(2015) were able to demonstrate prosocial effects of subchronic
oxytocin in adolescent C57BL/6J mice, the oxytocin treatment did
not reverse social deﬁcits induced by the NMDA antagonist keta-
mine, in contrast to our present ﬁndings with the NMDA receptor
knockdown mice.
The Grin1neo/neo mouse was originally proposed as a model of
schizophrenia (Mohn et al., 1999). Recent clinical studies in subjects
with schizophrenia have suggested that oxytocin could have ther-
apeutic efﬁcacy for deﬁcits in emotion recognition, attribution bias,
and other aspects of social cognition, following acute (Davis et al.,
2013; Fischer-Shofty et al., 2013; Woolley et al., 2014) or chronic
(Pedersen et al., 2011) treatment. In addition, 2-to-8 week regimens
of intranasal oxytocin have been reported to alleviate more general
positive and negative symptoms in schizophrenia (Feifel et al.,
2010; see Pedersen, 2014 for review), suggesting that oxytocin
might have broader antipsychotic-like activity. Work in rodent
models has demonstrated antipsychotic-like effects of acuteoxytocin or oxytocin agonists on sensorimotor gating deﬁcits (Feifel
et al., 2012; Ring et al., 2010), although Huang et al. (2014) did not
observe changes in prepulse inhibition following chronic oxytocin
in C57BL/6J. In the present studies, neither acute nor subchronic
oxytocin reversed impaired prepulse inhibition in Grin1neo/neo
mice, providing evidence that antipsychotic-like oxytocin action is
dependent upon the particular animal model.
We also evaluated the effects of chronic antipsychotic treatment
on social deﬁcits in the Grin1 knockdown model. Currently, only
two drugs have FDA approval for treatment of ASD, risperidone and
aripiprazole. While these drugs have been found to have some
beneﬁts against irritability in ASD, there is still no standard treat-
ment for impaired social behavior (Chadman, 2014). Similarly,
atypical antipsychotics generally have modest-to-poor efﬁcacy
against social deﬁcits in schizophrenia (Penn et al., 2009; Roberts
et al., 2010). Studies in the BTBR TþItpr3tf/J and Cntnap2/ mouse
models of ASD-like behavior have shown that acute risperidone
does not reverse sociability deﬁcits (Chadman, 2011; Gould et al.,
2011; Pe~nagarikano et al., 2011; Silverman et al., 2010). Further,
Mielnik et al. (2014) did not observe increased sociability following
acute clozapine in mice with deﬁcient NMDA receptor function.
However, the question remained whether chronic antipsychotic
intervention, initiated in early adolescence or young adulthood,
could alleviate the severity of social impairment. In the present
study, we found that chronic clozapine or risperidone failed to
rescue social deﬁcits in Grin1neo/neo mice. Further, although acute
treatment with these agents can ameliorate impaired sensorimotor
gating in the Grin1 model (Duncan et al., 2006a,b), chronic expo-
sure did not alter performance in the acoustic startle task in either
wild-type or knockdown mice.
Overall, these results point to a unique and selective prosocial
efﬁcacy for oxytocin. Together with our previous ﬁndings in BALB/
cByJ, we have demonstrated that a subchronic oxytocin regimen
can lead to persistent enhancement of sociability across three
models with divergent genotypes and behavioral proﬁles, sug-
gesting the possibility of generalized therapeutic beneﬁts across
the autism spectrum disorders, as well as other neuro-
developmental disorders characterized by social impairment.
Further studies with this panel of models could identify common
abnormalities in signaling pathways underlying deﬁcits in social
approach, as well as the mechanism of action for adaptive changes
in brain with subchronic oxytocin intervention.
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